Category Archives: RedHill Biopharma Ltd

RedHill Biopharma Announces Proposed Public Offering of its American Depositary Shares

| November 8, 2017 | Web Desk | 0

TEL-AVIV, Israel and RALEIGH, N.C., Nov. 07, 2017 (GLOBE NEWSWIRE) — RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary drugs for gastrointestinal and inflammatory diseases and cancer, today announced that it intends to offer its American Depositary Shares […]

RedHill Biopharma Announces Positive Top-Line Results from Phase II Study of BEKINDA® in Patients with Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)

| October 3, 2017 | Web Desk | 0

BEKINDA®i 12 mg Phase II study successfully met its primary endpoint, improving primary efficacy outcome of stool consistency by an absolute difference of 19.4% vs. placebo and comparing favorably with previously reported outcomes from studies of Xifaxan® (rifaximin) and Viberzi® (eluxadoline)ii IBS is one of the most common gastrointestinal disorders, affecting an estimated 30 million […]

RedHill Biopharma Announces Last Patient Visit in BEKINDA® Phase II Study for IBS-D

| July 17, 2017 | Web Desk | 0

Top-line results are expected in September 2017 The randomized, double-blind, placebo-controlled Phase II study is evaluating the safety and efficacy of BEKINDA® (RHB-102) 12 mg in 127 U.S. patients with diarrhea-predominant irritable bowel syndrome (IBS-D), with a primary endpoint of response in stool consistency as compared to baseline IBS is one of the most common […]

RedHill Biopharma Announces Enrollment of Last Patient in the BEKINDA® Phase II Study for IBS-D

| April 24, 2017 | Web Desk | 0

op-line results are expected in the third quarter of 2017  The randomized, double-blind, placebo-controlled Phase II study is evaluating the safety and efficacy of BEKINDA® (RHB-102) 12 mg in 127 U.S. patients with diarrhea-predominant irritable bowel syndrome (IBS-D) IBS is one of the most common gastrointestinal disorders; it is estimated that at least 30 million […]

RedHill Biopharma Announces Exclusive U.S. License from Entera Health for Commercial GI Product EnteraGam®

| April 5, 2017 | Web Desk | 0

RedHill expects to initiate U.S. promotion of its two commercially-available gastrointestinal specialty products, Donnatal®1 and EnteraGam®2, in mid-2017 Under the terms of the agreement, RedHill will pay Entera Health royalties on net sales generated from the sale of EnteraGam® by RedHill TEL-AVIV, Israel, April 05, 2017 (GLOBE NEWSWIRE) — RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) […]

RedHill Biopharma Receives FDA Orphan Drug Designation for YELIVA® for the Treatment of Cholangiocarcinoma

| April 4, 2017 | Web Desk | 0

Orphan Drug designation allows RedHill to benefit from various development incentives to develop YELIVA® (ABC294640) for cholangiocarcinoma, as well as a seven-year marketing exclusivity period for the indication, if approved for marketing A Phase IIa clinical study with YELIVA® in patients with advanced, unresectable, intrahepatic and extrahepatic cholangiocarcinoma is planned to be initiated in the […]

RedHill Biopharma Reports 2016 Fourth Quarter and Full-Year Financial Results

| February 23, 2017 | Web Desk | 0

RedHill maintains a strong and debt-free balance sheet with approximately $66 million in cash and cash equivalents at the end of 2016, allowing the Company to continue to execute its development and U.S. commercialization plans Select 2016 milestones include: Successful final results from the first Phase III study with RHB-105 for the treatment of H. […]

To Top